Ting-Ruei Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ting-Ruei Liang has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Ho Yin Pekkle Lam
Tzu Chi University, Taiwan; Tzu Chi University, Taiwan; Tzu Chi University, Taiwan
1 shared publication - Shih-Yi Peng
Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, Taiwan
1 shared publication
Latest Publications
- Open Access
- 23 June 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (6) , e0009554
Ameliorative effects of Schisandrin B on Schistosoma mansoni-induced hepatic fibrosis in vivo
Schistosomiasis is second only to malaria as the most devastating parasitic disease in the world. It is caused by the helminthsSchistosoma mansoni(S.mansoni),S.haematobium, orS.japonicum. Typically, patients with schistosomiasis suffer from symptoms of liver fibrosis and hepatosplenomegaly. Currently, patients were treated with praziquantel. Although praziquantel effectively kills the worm, it cannot prevent re-infection or resolve liver fibrosis. Also, current treatment options are not ample to completely cure liver fibrosis and splenic damages. Moreover, resistance of praziquantel has been reported in vivo and in vitro studies. Therefore, finding new effective treatment agents is urgently needed. Schisandrin B (Sch B) ofSchisandra chinensishas been shown to protect against different liver injuries including fatty liver disease, hepatotoxicity, fibrosis, and hepatoma. We herein investigate the potential of using Sch B to treatS.mansoni-induced liver fibrosis. Results from the present study demonstrate that Sch B is beneficial in treatingS.mansoni-induced liver fibrosis and splenic damages, through inhibition of inflammasome activation and apoptosis; and aside from that regulates host immune responses. Besides, Sch B treatment damages male adult worm in the mice, consequently helps to reduce egg production and lessen the parasite burden.
- 23 June 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (6) , e0009554
Open AccessAmeliorative effects of Schisandrin B on Schistosoma mansoni-induced hepatic fibrosis in vivo
Schistosomiasis is second only to malaria as the most devastating parasitic disease in the world. It is caused by the helminthsSchistosoma mansoni(S.mansoni),S.haematobium, orS.japonicum. Typically, patients with schistosomiasis suffer from symptoms of liver fibrosis and hepatosplenomegaly. Currently, patients were treated with praziquantel. Although praziquantel effectively kills the worm, it cannot prevent re-infection or resolve liver fibrosis. Also, current treatment options are not ample to completely cure liver fibrosis and splenic damages. Moreover, resistance of praziquantel has been reported in vivo and in vitro studies. Therefore, finding new effective treatment agents is urgently needed. Schisandrin B (Sch B) ofSchisandra chinensishas been shown to protect against different liver injuries including fatty liver disease, hepatotoxicity, fibrosis, and hepatoma. We herein investigate the potential of using Sch B to treatS.mansoni-induced liver fibrosis. Results from the present study demonstrate that Sch B is beneficial in treatingS.mansoni-induced liver fibrosis and splenic damages, through inhibition of inflammasome activation and apoptosis; and aside from that regulates host immune responses. Besides, Sch B treatment damages male adult worm in the mice, consequently helps to reduce egg production and lessen the parasite burden.